Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Single-unit cord blood transplantation reduces the risk of relapse and improves leukemia-free survival compared to other donor sources in allo-HSCT for patients with high-risk acute myeloid leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

MKMika KunoOWOtoya WatanabeDKDaisuke Kaji

Discussion

Loading...

Member takes

Overview

Analysis shows lower relapse rates and better leukemia-free survival with cord blood in high-risk AML, suggesting it as a favorable donor option.

Key Points

  • This research investigates the efficacy of cord blood transplantation in improving outcomes for high-risk acute myeloid leukemia (AML).
  • Retrospective analysis of 488 high-risk AML patients undergoing first allo-HSCT between 2008 and 2024.
  • Comparison of cord blood and other donor sources for leukemia-free survival, overall survival, and relapse rates.
  • Propensity score matching to adjust for baseline differences.
  • Multivariate analysis using Cox proportional hazards model.
  • Cord blood recipients had a leukemia-free survival rate of 49.6% compared to 35.4% with other donors in the matched cohort (p=0.03).
  • Cumulative incidence of relapse was significantly lower in cord blood at 21.7% compared to 42.8% in other sources (p<0.01).
  • Overall survival was similar between the two groups (55.6% for cord blood, 44.4% for others, p=0.30).

Cite This Study

Kuno et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d936https://doi.org/10.1182/blood-2025-591
View Full Paper
Ask AI
Bookmark
Share